MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Biogen Inc

Geschlossen

BrancheGesundheitswesen

130.65 -0.48

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

130

Max

132.92

Schlüsselkennzahlen

By Trading Economics

Einkommen

-122M

267M

Verkäufe

-15M

2.5B

KGV

Branchendurchschnitt

12.24

63.778

EPS

3.44

Gewinnspanne

10.865

Angestellte

7,605

EBITDA

-158M

536M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+46.54% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-982M

20B

Vorheriger Eröffnungskurs

131.13

Vorheriger Schlusskurs

130.65

Nachrichtenstimmung

By Acuity

35%

65%

111 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Biogen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Sept. 2024, 11:00 UTC

Top News

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. Mai 2024, 15:56 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Peer-Vergleich

Kursveränderung

Biogen Inc Prognose

Kursziel

By TipRanks

46.54% Vorteil

12-Monats-Prognose

Durchschnitt 192.43 USD  46.54%

Hoch 265 USD

Tief 135 USD

Basierend auf 25 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Biogen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

25 ratings

13

Buy

12

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 141.43Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

111 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.